Neurophysiology

NUTRACEUTICAL INNOVATOR STEMREGEN® BOLSTERS LEADERSHIP TEAM WITH INDUSTRY INSIDERS FOCUSED ON EXPANSION GOALS

Retrieved on: 
木曜日, 4月 25, 2024
Rejuvenation, Kenexa, Health, Research, B cell, Science, Master of Science, Neurophysiology, Ageing, Management

Its flagship product is a clinically tested blend of natural ingredients that support stem cell release and migration, fostering healthy aging and rejuvenation from within.

Key Points: 
  • Its flagship product is a clinically tested blend of natural ingredients that support stem cell release and migration, fostering healthy aging and rejuvenation from within.
  • Drapeau named Ryan Riley, former Chief Executive Officer of Microbe Formulas and CellCore Biosciences, as his successor as CEO.
  • Riley was previously an advisor to the company and brings deep industry experience leading companies through stages of prolific growth.
  • For more information about the brand and its scientific inventor and founder, follow @StemCellChristian on TikTok and Instagram, and @Stemregen on Instagram.

Scialog: Neurobiology and Changing Ecosystems to Launch in 2025

Retrieved on: 
木曜日, 4月 11, 2024
Kavli Foundation, Genetics, Allen Institute, Cell biology, Research, Thought, Research Corporation, Innovation, Neuroscience, RCSA, Partnership, Nervous system, Physiology, Neurophysiology, RSCA, Toxicology, Management

The process aims to spark creative and novel ideas for transformative research.

Key Points: 
  • The process aims to spark creative and novel ideas for transformative research.
  • The first meeting of Scialog: Neurobiology and Changing Ecosystems will be held March 13 – 16, 2025, in Tucson, Arizona.
  • The series of meetings will complement The Kavli Foundation's Neurobiology and Changing Ecosystems multi-year initiative launched in 2023, supporting research investigating how neural processes—including molecular, cellular, and circuit-level mechanisms—are impacted by or resilient to changing environments.
  • For full consideration as a Fellow for the first meeting of Scialog: Neurobiology and Changing Ecosystems, nominate yourself or an early career colleague by September 1, 2024.

OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial

Retrieved on: 
木曜日, 3月 21, 2024
Visual Science, Uveitis, Wilmer Ophthalmological Institute, Brandeis University, Neurophysiology, NCP, BID, Telecanthus, Research, KOL, University, Patient, Doctor of Philosophy, Bascom Palmer Eye Institute, DED, Georgetown University Medical Center, Pain, Therapy, Johns Hopkins Hospital, Medical director, FDA, Pharmaceutical industry

LONDON and NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announces that it will be hosting a Key Opinion Leader (KOL) event on April 9th, 2024 at 12:00 PM ET to discuss in depth the findings of the new and comprehensive efficacy data readout from the Phase 2 trial of OK-101 in dry eye disease, which will be announced on March 22nd, 2024.

Key Points: 
  • OKYO Pharma’s management team will also be in attendance to present an overview of OK-101’s mechanism of action.
  • He has published over 200 peer-reviewed articles and has served on the editorial boards of several prestigious ophthalmology journals.
  • Additionally, statistically significant improvements were observed in both a “sign” (total conjunctival staining) and two “symptoms” (burning/stinging and blurred vision), which are FDA-recognized endpoints of dry eye disease.
  • The double-masked, randomized, placebo-controlled Phase 2 trial was conducted at six sites in the U.S. and enrolled 240 subjects with DED dosed twice-daily (BID).

ImmunoBrain Checkpoint Appoints Dr. Sanjay Keswani as Chief Executive Officer

Retrieved on: 
月曜日, 1月 22, 2024
Bristol Myers Squibb, Neurophysiology, Patient, MD, Sanjay, Medicine, St Bartholomew's Hospital, Johns Hopkins Hospital, Johns Hopkins, Royal College of Physicians, Immunology, Saint Mary's Hospital, Acquisition, Royal college, Bachelor of Science, CMO, IPO, Bartholomew the Apostle, Fibrosis, Hospital, Series A round, FRCP, Roche, Faricimab, Growth, Pharmaceutical industry

NEW YORK, Jan. 22, 2024 /PRNewswire/ -- ImmunoBrain Checkpoint Inc. (ImmunoBrain), a clinical stage biopharmaceutical company developing innovative disease-modifying immune therapies to combat neurodegenerative diseases, today announced the appointment of Dr. Sanjay Keswani, MD, BSc, FRCP, as its President and Chief Executive Officer.

Key Points: 
  • NEW YORK, Jan. 22, 2024 /PRNewswire/ -- ImmunoBrain Checkpoint Inc. (ImmunoBrain), a clinical stage biopharmaceutical company developing innovative disease-modifying immune therapies to combat neurodegenerative diseases, today announced the appointment of Dr. Sanjay Keswani, MD, BSc, FRCP, as its President and Chief Executive Officer.
  • Dr. Keswani is an accomplished physician-scientist with executive leadership experience in both large pharma and small biotech companies.
  • "As a physician-scientist and seasoned biotech executive, Dr. Keswani possesses both the business acumen and the R&D expertise required to serve as Chief Executive Officer of ImmunoBrain," stated Nathan Hevrony, Co-founder and Executive Chairman of ImmunoBrain.
  • I am privileged to work with the ImmunoBrain team and Professor Michal Schwartz whose groundbreaking seminal research has formed the foundation of ImmunoBrain," stated Dr. Sanjay Keswani.

Medical Students Discover Antidote for Anxiety, Stress

Retrieved on: 
金曜日, 1月 19, 2024
Student, Neuroscience, Death, MD, Physiology, Health, Loyola University, Life, EEG, Female, Male, Cardiology, Transcendence, Neurophysiology, Suicide, Anxiety, Endocrinology, Health policy, Nursing, Brain, Physician

MAYWOOD, Ill., Jan. 19, 2024 /PRNewswire/ -- America's youngest doctors and medical students are overwhelmed with anxiety, stress, and burnout: 300 to 400 physicians a year in the US take their own life.

Key Points: 
  • MAYWOOD, Ill., Jan. 19, 2024 /PRNewswire/ -- America's youngest doctors and medical students are overwhelmed with anxiety, stress, and burnout: 300 to 400 physicians a year in the US take their own life.
  • 9.4% of fourth-year medical students and residents reported suicidal thoughts in the prior 2 weeks.
  • A self-care strategy described as effective by medical students is documented in a newly published study.
  • The current study reports Loyola Stritch medical students' outcomes in their own words:
    1.

 Virpax Pharmaceuticals Announces Leadership Transition

Retrieved on: 
金曜日, 11月 17, 2023
Biotechnology, Health, Finance, Other Health, Pharmaceutical, Surgery, Professional Services, Other Science, Practice Management, Medical Devices, Infectious Diseases, Hospitals, Science, Veterinary, CNS, Neurogenic inflammation, Silence Therapeutics, Meharry Medical College, Pharmaceutical marketing, Regulatory affairs, Therapy, Post-traumatic stress disorder, Quality assurance, Lincoln University, Commercial Operating System, Pain management, Patient, INSEAD, Merck, Medication, Clobazam, Nitrome, Sanofi, Trustee, Novartis, University, Harvard Medical School, Axovant Sciences, Tennessee State University, Champaign–Urbana metropolitan area, Central nervous system, Business, DSM-IV codes, International business, Pharmaceutical industry, Management, Analgesic, Schizophrenia, Biology, Neurophysiology, Lundbeck, Neuroscience, Droxidopa

Prior to Virpax, Mr. Bruce served as Vice President of sales for Danone Specialized Nutrition North America, Danone’s medical nutrition division.

Key Points: 
  • Prior to Virpax, Mr. Bruce served as Vice President of sales for Danone Specialized Nutrition North America, Danone’s medical nutrition division.
  • He has a BA from Lincoln University and a Master’s degree in Leadership from Georgetown University’s McDonough School of Business.
  • Aside from Virpax Pharmaceuticals, he also serves on the board of Advent Therapeutics Inc. and is a member of the Board of Trustees of Meharry Medical College.
  • I am proud of what we have accomplished together and confident that Virpax under Gerald and Eric’s leadership will remain on track to begin first-in-human trials in the coming year,” commented Mr. Mack.

Sight Sciences Appoints Matt Link as Chief Commercial Officer

Retrieved on: 
月曜日, 9月 11, 2023
Glaucoma, Sports medicine, University, Elective surgery, Orion, Innovation system, Spine, Partner (business rank), Telecanthus, Neurophysiology, NuVasive, Standard of care, Patient, Growth, Management

MENLO PARK, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today announced the appointment of Matthew Link as its Chief Commercial Officer, effective September 11, 2023.

Key Points: 
  • MENLO PARK, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today announced the appointment of Matthew Link as its Chief Commercial Officer, effective September 11, 2023.
  • “We are very excited to have Matt join Sight Sciences as we scale our Surgical Glaucoma and Dry Eye businesses.
  • Matt joined NuVasive at a time when it had similar revenue levels as Sight Sciences does today and helped scale NuVasive’s business over the ensuing years to profitability with over $1 billion in revenue,” said Paul Badawi, Founder and Chief Executive Officer of Sight Sciences.
  • I am ready to leverage my strong commercial strategy and development background in high-growth medtech to help Sight Sciences achieve its fullest potential.

Motus GI Appoints Medical Device Industry Veteran Scott Durbin to its Board of Directors

Retrieved on: 
水曜日, 9月 6, 2023
Yale University, Science, Orchestra, University, ASTM, Lehman Brothers, Health care, Research, PARS, Mergers and acquisitions, Patient, Physician, Physics, FDA, Vericel, Investment, Management, Motus, Biotronik, Neurophysiology

FORT LAUDERDALE, Fla., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes and experiences, announced the appointment of Scott Durbin to the Company’s Board of Directors (the “Board”).

Key Points: 
  • FORT LAUDERDALE, Fla., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes and experiences, announced the appointment of Scott Durbin to the Company’s Board of Directors (the “Board”).
  • “We are excited to have Scott join our Board.
  • During this time, he established strong industry knowledge across the life sciences industry, including substantial therapeutic clinical development and global commercialization experience.
  • Prior to joining Vericel, Mr. Durbin was Chief Financial Officer, Chief Operating Officer and Secretary of Board at Prescient Medical.

Rapid Pace of Environmental Change May Surpass Natural Adaptability of Neural Systems, Researchers Say

Retrieved on: 
火曜日, 8月 29, 2023
Climate Change, Health, Environmental Issues, Philanthropy, General Health, Neurology, Other Science, Research, Foundation, Environment, Science, Newton, Taste, Human, Partnership, University, National Centre for Biological Sciences, Kavli Foundation, Climate, Frontiers, Illinois State University, Environmental science, Newton International Fellowship, Light, Allen Institute for Brain Science, Multimedia, Brain, Cell, Biology, Movement, Government, Organization, Animal, Nervous system, University of Oxford, Ecology, Central University of South Bihar, Leiden University, Allen Institute, Agriculture, Management, Pharmaceutical industry, Neurophysiology

Understanding neural system response to rapidly changing ecosystems is vital for the ability to predict what may transpire with these changes and how neural systems may adapt or fail to adapt to them.

Key Points: 
  • Understanding neural system response to rapidly changing ecosystems is vital for the ability to predict what may transpire with these changes and how neural systems may adapt or fail to adapt to them.
  • View the full release here: https://www.businesswire.com/news/home/20230828470157/en/
    Researchers are pointing to opportunities to explore how environmental changes impact human and animal nervous systems, an area in which little is known.
  • “What we do in the lab is not sufficient to understand how the nervous system actually functions.
  • The Allen Institute also just launched a call for proposals to study the nervous system in rapidly changing environments.

Love or hate TikTok's viral bottle-smashing trend? A neuroscientist explains what that says about your brain

Retrieved on: 
木曜日, 8月 24, 2023
Psychology, YouTube, Food, Life, Noise, Friends, Electroencephalography, Anxiety, Rage, Misophonia, Nail, Spine, Anger, Research, Brain, Emotion, Scalp, Neurophysiology, ASMR, Laboratory, EEG, Quarterlife, Sound, Hyperacusis, Relaxation, Mental health, Family, Nightclub, Medical imaging, Consumer electronics

ASMR is often described as a relaxing, tingling sensation experienced in the scalp or the spine.

Key Points: 
  • ASMR is often described as a relaxing, tingling sensation experienced in the scalp or the spine.
  • This article is part of Quarter Life, a series about issues affecting those of us in our twenties and thirties.
  • The articles in this series explore the questions and bring answers as we navigate this turbulent period of life.

ASMR research

    • Research into the electrical activity of the brain may shed some light on the neurophysiology that underpins ASMR experiences.
    • Interestingly, one of the reasons that ASMR videos have gained such popularity is their ability to influence relaxation.
    • Research indicates that ASMR-prone people may also tend to experience anxiety and that ASMR-inducing videos may help to alleviate it.

What it means if you don’t like bottle-smashing videos

    • Some people experience hyperacusis, where everyday sounds – such as something smashing – are perceived as loud and uncomfortable, even painful to listen to.
    • Such experiences may be underpinned by increased levels of activity in parts of the brain that process sound.
    • Indeed, some people even experience misophonia, whereby some sounds lead to an intensely unpleasant emotional or physiological reaction, such as anger.
    • This may in part explain why the same sound can yield very different feelings in different people when watching bottle-smashing videos.